Page 72 - AN-3-2

Advanced Neurology Inflammation in diabetic stroke: Treatment target

adiponectin from adipocytes. Am J Physiol Endocrinol 2008;283(49):34457-34468.
Metab. 2006;291(5):E1100-E1105.
doi: 10.1074/jbc.M801465200
doi: 10.1152/ajpendo.00187.2006
47. Senatus L, Egana-Gorrono L, Lopez-Diez R, et al. DIAPH1
37. Liu J, Wang LN. Peroxisome proliferator-activated receptor mediates progression of atherosclerosis and regulates hepatic
gamma agonists for preventing recurrent stroke and other lipid metabolism in mice. Commun Biol. 2023;6(1):280.
vascular events in people with stroke or transient ischaemic doi: 10.1038/s42003-023-04643-2
attack. Cochrane Database Syst Rev. 2023;1(1):CD010693.
48. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin
doi: 10.1002/14651858.CD010693.pub6
to prevent vascular events in men and women with elevated
38. Zhao D, Sohouli MH, Rohani P, et al. The effect of metformin C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
on adipokines levels: A systematic review and meta-analysis doi: 10.1056/NEJMoa0807646
of randomized-controlled trials. Diabetes Res Clin Pract.
2023;207:111076. 49. Alikiaii B, Heidari Z, Bagherniya M, Askari G, Sathyapalan T,
Sahebkar A. The effect of statins on C-reactive protein
doi: 10.1016/j.diabres.2023.111076
in stroke patients: A systematic review of clinical trials.
39. Flynn MC, Kraakman MJ, Tikellis C, et al. Transient Mediators Inflamm. 2021;2021:7104934.
intermittent hyperglycemia accelerates atherosclerosis by doi: 10.1155/2021/7104934
promoting myelopoiesis. Circ Res. 2020;127(7):877-892.
50. Distel E, Barrett TJ, Chung K, et al. miR33 inhibition
doi: 10.1161/CIRCRESAHA.120.316653
overcomes deleterious effects of diabetes mellitus on
40. Bjork P, Bjork A, Vogl T, et al. Identification of human atherosclerosis plaque regression in mice. Circ Res.
S100A9 as a novel target for treatment of autoimmune 2014;115(9):759-769.
disease via binding to quinoline-3-carboxamides. PLoS Biol. doi: 10.1161/CIRCRESAHA.115.304164
2009;7(4):e97.
51. Enlimomab Acute Stroke Trial Investigators. Use of anti-
doi: 10.1371/journal.pbio.1000097
ICAM-1 therapy in ischemic stroke: Results of the enlimomab
41. Imazio M, Nidorf M. Colchicine and the heart. Eur Heart J. acute stroke trial. Neurology. 2001;57(8):1428-1434.
2021;42(28):2745-2760.
doi: 10.1212/wnl.57.8.1428
doi: 10.1093/eurheartj/ehab221
52. Mocco J, Choudhri T, Huang J, et al. HuEP5C7 as a
42. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in humanized monoclonal anti-E/P-selectin neurovascular
patients with chronic coronary disease. N Engl J Med. protective strategy in a blinded placebo-controlled trial of
2020;383(19):1838-1847. nonhuman primate stroke. Circ Res. 2002;91(10):907-914.
doi: 10.1056/NEJMoa2021372 doi: 10.1161/01.res.0000042063.15901.20
43. Puig N, Sole A, Aguilera-Simon A, et al. Novel therapeutic 53. National Institute of Neurological Disorders and Stroke
approaches to prevent atherothrombotic ischemic stroke (NINDS). E-Selectin Nasal Spray to Prevent Stroke
in patients with carotid atherosclerosis. Int J Mol Sci. Recurrence. Bethesda, MD: National Library of Medicine
2023;24(18):14325. (US); 2000. Available from: https://clinicaltrials.gov/show/
NCT00012454 [Last accessed on 2016 May 21].
doi: 10.3390/ijms241814325
54. Elkind MSV, Veltkamp R, Montaner J, et al. Natalizumab in
44. Boczar KE, Shin S, deKemp RA, et al. The Canadian study
of arterial inflammation in patients with diabetes and acute ischemic stroke (ACTION II): A randomized, placebo-
recent vascular events, evaluation of colchicine effectiveness controlled trial. Neurology. 2020;95(8):e1091-e1104.
(CADENCE): Protocol for a randomised, double-blind, doi: 10.1212/WNL.0000000000010038
placebo-controlled trial. BMJ Open. 2023;13(11):e074463.
55. Krams M, Lees KR, Hacke W, et al. Acute stroke therapy
doi: 10.1136/bmjopen-2023-074463 by inhibition of neutrophils (ASTIN): An adaptive dose-
response study of UK-279,276 in acute ischemic stroke.
45. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory
therapy with canakinumab for atherosclerotic disease. Stroke. 2003;34(11):2543-2548.
N Engl J Med. 2017;377(12):1119-1131. doi: 10.1161/01.STR.0000092527.33910.89
doi: 10.1056/NEJMoa1707914 56. Levard D, Buendia I, Lanquetin A, Glavan M, Vivien D,
Rubio M. Filling the gaps on stroke research: Focus
46. Hudson BI, Kalea AZ, Del Mar Arriero M, et al. Interaction
of the RAGE cytoplasmic domain with diaphanous-1 on inflammation and immunity. Brain Behav Immun.
is required for ligand-stimulated cellular migration 2021;91:649-667.
through activation of Rac1 and Cdc42. J Biol Chem. doi: 10.1016/j.bbi.2020.09.025

Volume 3 Issue 2 (2024) 11 doi: 10.36922/an.1694